Doty RL, Tourbier IA, Pham DL, Cuzzocreo JL, Udupa JK, Karacali B, Beals E, Fabius L, Leon-Sarmiento FE, Moonis G, Kim T, Mihama T, Geckle RJ, Yousem DM.
J Neurol. 2016 Apr;263(4):677-88. doi: 10.1007/s00415-016-8030-6. Epub 2016 Jan 25.
PMID:26810729
Management approach including pembrolizumab for fingolimod-associated progressive multifocal leukoencephalopathy in a patient with relapsing-remitting multiple sclerosis.
Barritt AW, Das E, Morley N, Seymour M, Saha R, Vera J, Vundavalli S, Dizdarevic S, Nicholas R, Berger JR, Fisniku LK.
Mult Scler. 2023 Feb;29(2):301-306. doi: 10.1177/13524585221137279. Epub 2022 Nov 30.
QSM is an imaging biomarker for chronic glial activation in multiple sclerosis lesions.
Gillen KM, Mubarak M, Park C, Ponath G, Zhang S, Dimov A, Levine-Ritterman M, Toro S, Huang W, Amici S, Kaunzner UW, Gauthier SA, Guerau-de-Arellano M, Wang Y, Nguyen TD, Pitt D.
Ann Clin Transl Neurol. 2021 Apr;8(4):877-886. doi: 10.1002/acn3.51338. Epub 2021 Mar 11.
PMID:33704933
Magnetic resonance imaging changes following natalizumab discontinuation in multiple sclerosis patients with progressive multifocal leukoencephalopathy.